Big Data in medicine

Tasks and effect

2018: Why to pharmgigant Big Data about health of patients

Pharmproizvoditeli aim to get access to medical data of patients and competing in speed conclude bargains with the technology companies expert in area of the analysis of Big Data - the tool which opens new opportunities for understanding of how drugs in real life, said in the publication of Reuters of March 1, 2018 work.

One of fresh examples - the transaction of Roche announced in February, 2018 within which the company for $2 billion acquires all shares of a startup Flatiron Health specializing in collecting of clinical these oncological patients.

Pharmproizvoditeli aim to get access to medical data of patients and competing in speed conclude bargains with the technology companies expert in area of the analysis of Big Data

Studying of real certificates allows pharmproizvoditel to prove usefulness and values of the drugs. The most actively similar researches are conducted in the field of oncology, diseases of heart and respiratory frustration.

Data on real practice of use of medicines are collected outside traditional randomized clinical trials which are the gold standard of assessment of drugs today, and interest in this sphere promptly grows.

A half of 1800 clinical trials conducted since 2006 using data from real life was begun in the last three years, and in the 2017th their number reached record 300, the Reuters agency with reference to data from the website clinicaltrials.gov where information on the international clinical trials is placed reported.

Trace as drugs in daily clinical practice work, it was always difficult, but with digitalization of medicine, implementation of wearable electronics and social networks new opportunities for data collection appear. The medicine becomes more personalized therefore information on experience of real patients who represent broader selection than rather narrow circle of the people participating in traditional clinical trials purchases special importance.

As of March, 2018 all largest pharmaceutical companies of the world have divisions which are engaged in collecting and use of real data on different diseases, and some producers already conducted scientific research using the acquired information for deeper understanding of mechanisms of effect of the drugs. Among like those - a research in the field of diabetes of the companies AstraZeneca and Sanofi, joint researches Pfizer and Bristol-Myers Squibb in the field of prevention of a stroke and also the project Takeda Pharmaceutical devoted to intestines diseases.

Traditional clinical trials become more and more expensive therefore the pharmaceutical industry looks for opportunities to achieve the same results using data which are collected in a planned order — Paul Taylor, the expert in application of computer sciences in the field of health care of University College London comments.

The specialist added that all this became possible thanks to the growing digitalization of medical these patients. Important, as regulators welcome this trend.

The head of the American Food and Drug Administration (FDA) Scott Gottlieb considers that wider use of real certificates is capable to cut down expenses on development of drugs and to help doctors to make the best decisions in the field of medicine.

Colleagues from the European agency on medicines (European Medicines Agency, EMA) also study possibilities of use of real certificates in decision making process.^[1]

Шаблон:Subject Medicine

You See Also